A significant component of the TME in CHL is cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a regulatory molecule that can inhibit the immune response, therefore decreasing the ability of the immune system to destroy tumour cells and is related to tumour aggressiveness. This evidence concerns the gene CTLA4 and neoplasm.